Soleno Therapeutics (SLNO) Treasury Shares (2013 - 2026)
Soleno Therapeutics (SLNO) posted quarterly Treasury Shares of $1.2 million for Q1 2026, up 220.05% year-over-year from $361991.0 in Q1 2025, and up 161.35% quarter-over-quarter from $443291.0 in Q4 2025.
Soleno Therapeutics (SLNO) Treasury Shares (2013 - 2026) Analysis & Trends
Soleno Therapeutics (SLNO) has reported Treasury Shares for 12 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Treasury Shares rose 220.05% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (up 220.05% YoY), while the FY2025 annual figure was $443291.0, down 52.83% from the prior year.
- Treasury Shares grew to $1.2 million in Q1 2026 per SLNO's latest filing, from $443291.0 in the prior quarter.
- Across five years, Treasury Shares topped out at $1.2 million in Q1 2026 and bottomed at $9534.0 in Q1 2023.
- Historically, Treasury Shares has averaged $409174.1 across 5 years, with a median of $361991.0 in 2025.
- Annual changes were most pronounced in 2023 — Treasury Shares tumbled 96.7% — and 2024, when it soared 5950.37%.
- Soleno Therapeutics' Treasury Shares stood at $19068.0 in 2022, then retreated by 18.53% to $15534.0 in 2023, then jumped by 5950.37% to $939865.0 in 2024, then plunged by 52.83% to $443291.0 in 2025, then jumped by 161.35% to $1.2 million in 2026.
- Business Quant data shows SLNO's Treasury Shares at $1.2 million in Q1 2026, $443291.0 in Q4 2025, and $469769.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 5.08 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.72 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 92,219.00 |
| 10 | Soleno Therapeutics | 2.74 Bn | 2.49 Bn | 93.41 Mn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.16 Mn |
| Mar 31, 2026 | 1.16 Mn |
| Dec 31, 2025 | 443,291.00 |
| Dec 31, 2025 | 443,291.00 |
| Sep 30, 2025 | 469,769.00 |
| Sep 30, 2025 | 469,769.00 |
| Jun 30, 2025 | 468,457.00 |
| Jun 30, 2025 | 468,457.00 |
| Mar 31, 2025 | 361,991.00 |
| Mar 31, 2025 | 361,991.00 |
| Dec 31, 2024 | 939,865.00 |
| Dec 31, 2024 | 939,865.00 |
| Sep 30, 2024 | 1.07 Mn |
| Sep 30, 2024 | 1.07 Mn |
| Jun 30, 2024 | 256,030.00 |
| Jun 30, 2024 | 256,030.00 |
| Mar 31, 2024 | 299,280.00 |
| Mar 31, 2024 | 299,280.00 |
| Dec 31, 2023 | 15,534.00 |
| Dec 31, 2023 | 15,534.00 |